Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
The study evaluated the development of drug resistance in a group of HIV-1 patients. After failure to respond to previous therapy with two non-nucleoside reverse transcriptase inhibitors (NNRTIs), as assessed by the presence of a rebound in viral load or a constant high level of HIV plasma viraemia, the patients were treated with a combination of stavudine, lamivudine and efavirenz (EFV). Results showed that viruses carrying primary mutations, usually K103N, T215Y and M41L, presented higher levels of HIV-1 RNA, suggesting an association between a precise mutation pattern and treatment failure.
Re
M C
MC
Section of Microbiology, Department of Clinical and Experimental Medicine, St Orsola Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. remc@med.unibo.it
Monari
P
P
Bon
I
I
Borderi
M
M
Gibellini
D
D
Schiavone
P
P
Vitone
F
F
Furlini
G
G
La Placa
M
M
D000480:Alkynes; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D024882:Drug Resistance, Viral; D005814:Genes, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology* / Q000627:therapeutic use; D009154:Mutation / Q000235:genetics; D010078:Oxazines / Q000494:pharmacology* / Q000627:therapeutic use; D012367:RNA, Viral / Q000032:analysis; D018119:Stavudine / Q000494:pharmacology* / Q000627:therapeutic use; D019562:Viral Load; D014766:Viremia / Q000821:virology
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D012367:RNA, Viral; D019259:Lamivudine; D018119:Stavudine; C098320:efavirenz